Exploring the NK cell platform for cancer immunotherapy

JA Myers, JS Miller - Nature reviews Clinical oncology, 2021 - nature.com
Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system that are
capable of killing virally infected and/or cancerous cells. Nearly 20 years ago, NK cell …

Graft-versus-host disease

JLM Ferrara, JE Levine, P Reddy, E Holler - The Lancet, 2009 - thelancet.com
Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk
haematological malignant disorders and other life-threatening haematological and genetic …

Risk factors for acute GVHD and survival after hematopoietic cell transplantation

M Jagasia, M Arora, MED Flowers… - Blood, The Journal …, 2012 - ashpublications.org
Risk factors for acute GVHD (AGVHD), overall survival, and transplant-related mortality were
evaluated in adults receiving allogeneic hematopoietic cell transplants (1999-2005) from …

[HTML][HTML] Defining the intensity of conditioning regimens: working definitions

A Bacigalupo, K Ballen, D Rizzo, S Giralt… - Biology of blood and …, 2009 - Elsevier
Defining conditioning regimen intensity has become a critical issue for the hemopoietic stem
cell transplant (HSCT) community. In the present report we propose to define conditioning …

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

ML Sorror, MB Maris, R Storb, F Baron, BM Sandmaier… - Blood, 2005 - ashpublications.org
We previously reported that the Charlson Comorbidity Index (CCI) was useful for predicting
outcomes in patients undergoing allogeneic hematopoietic cell transplantation (HCT) …

Acute myeloid leukaemia

E Estey, H Döhner - The Lancet, 2006 - thelancet.com
Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haemopoietic
progenitor cells and the most common malignant myeloid disorder in adults. The median …

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

JJ Cornelissen, A Gratwohl, RF Schlenk… - Nature reviews Clinical …, 2012 - nature.com
Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …

Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable …

DP Lu, L Dong, T Wu, XJ Huang, MJ Zhang, W Han… - Blood, 2006 - ashpublications.org
The outcomes of 293 patients with leukemia undergoing HLA-identical sibling (n= 158) or
related HLA-mismatched (n= 135) hematopoietic cell transplantation (HCT) performed …

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic …

ML Sorror, BM Sandmaier, BE Storer, GN Franke… - Jama, 2011 - jamanetwork.com
Context A minimally toxic nonmyeloablative regimen was developed for allogeneic
hematopoietic cell transplantation (HCT) to treat patients with advanced hematologic …

[HTML][HTML] Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a Center for International Blood and Marrow …

ML Sorror, BR Logan, X Zhu, JD Rizzo… - Biology of Blood and …, 2015 - Elsevier
Prospective validation of the hematopoietic cell transplantation–comorbidity index (HCT-CI)
using contemporary patients treated with hematopoietic cell transplantation (HCT) across …